The Developmental Research Program of the University of Pittsburgh Cancer Institute Lung Cancer SPORE? will be carried out for the purpose of identifying and facilitating innovative new pilot projects in lung cancer? research. The overall goal of the Developmental Research Program is to provide seed funding to? investigators for novel research in lung cancer to further the basic, clinical and translational research? priorities of the Lung Cancer SPORE. The specific goals of this Program are : 1) to provide seed funding? opportunities for initial investigation of promising novel research in lung cancer: 2) to stimulate basic, clinical,? and translational lung cancer research in areas of high priority to the Lung Cancer SPORE; 3) to facilitate? development of pilot projects into full project status in the Lung Cancer SPORE or to be competitive for? independent investigator-initiated proposals to other funding agencies; and 4) to increase the visibility of? Lung Cancer SPORE activities and increase participation among the institution's clinicians and researchers.? Our design for the Developmental Research Program in the renewal is similar to the process used during the? first grant period. Drs. William L. Bigbee and Joel S. Greenberger will provide Program leadership for basic? and clinical research, respectively. The Developmental Research Program will utilize institutional web-based? resources and printed announcements to notify the research community at the UPCI, the University of? Pittsburgh Medical Center (UPMC), and the affiliated Carnegie Mellon University of the availability of? research funds to support pilot projects in lung cancer. In response to the new SPORE guideline? encouraging inter-institutional collaboration, we will also make the program available to our sister Cancer? Centers in Philadelphia, who are part of the statewide Pennsylvania Cancer Control Consortium (PAC-3)? initiative. A standing Developmental Research Program Committee, together with ad hoc reviewers with? specific expertise as needed drawn from the UPCI, UPMC, the Lung Cancer SPORE External Advisory? Board, or other SPOREs will provide rigorous and consistent peer review of the solicited project proposals.? The proposed Developmental Research Program budget will include $70,000 per year in funds from the NCI? through this proposal, together with an additional $50,000 per year in matching funds from the UPCI.? Proposals will be solicited and reviewed on an annual basis and grants of $30,000-$50,000 per year for 1-2? years will be awarded to the most meritorious proposals. These activities of the Developmental Research? Program will stimulate innovative research toward meeting the translations goals of the Lung Cancer? SPORE: reduction in the incidence, morbidity, and mortality from lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090440-08
Application #
7624400
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
8
Fiscal Year
2008
Total Cost
$109,040
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196
Rothenberger, Natalie J; Somasundaram, Ashwin; Stabile, Laura P (2018) The Role of the Estrogen Pathway in the Tumor Microenvironment. Int J Mol Sci 19:
Yochum, Zachary A; Cades, Jessica; Wang, Hailun et al. (2018) Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene :
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Volonte, Daniela; Vyas, Avani R; Chen, Chen et al. (2018) Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence. J Biol Chem 293:1794-1809
Hopkins, Kathleen G; Ferson, Peter F; Shende, Manisha R et al. (2017) Prospective study of quality of life after lung cancer resection. Ann Transl Med 5:204
Vendetti, Frank P; Leibowitz, Brian J; Barnes, Jennifer et al. (2017) Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. Sci Rep 7:41892
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944
Sun, Fan; Xiao, Gutian; Qu, Zhaoxia (2017) Isolation of Murine Alveolar Type II Epithelial Cells. Bio Protoc 7:
Dandachi, Nadine; Kelly, Neil J; Wood, John P et al. (2017) Macrophage Elastase Induces TRAIL-mediated Tumor Cell Death through Its Carboxy-Terminal Domain. Am J Respir Crit Care Med 196:353-363

Showing the most recent 10 out of 191 publications